查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016969

獸用和動物疫苗市場：2026-2032年全球市場預測（按產品類型、給藥途徑、目標疾病、技術平台、價態、動物類型、分銷管道和最終用戶分類）

Veterinary/Animal Vaccines Market by Product Type, Route Of Administration, Disease Indication, Technology Platform, Valency, Animal Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，獸藥和動物疫苗市場價值將達到 150.5 億美元，到 2026 年將成長到 160.5 億美元，到 2032 年將達到 240.1 億美元，複合年成長率為 6.89%。

主要市場統計數據
基準年 2025 150.5億美元
預計年份：2026年 160.5億美元
預測年份 2032 240.1億美元
複合年成長率 (%) 6.89%

對獸用疫苗市場進行全面概述，揭示影響策略的關鍵促進因素、相關人員的角色、技術進步以及與監管的互動。

獸用疫苗產業目前正經歷一場結構性變革，這場變革正在改變科學範式、商業策略以及生產者和服務供應商的企業發展。來自研究機構、臨床機構、畜牧企業和監管機構的相關人員團結一致，致力於改善疾病控制、提升動物福利和建立具有韌性的供應鏈。隨著科學基礎的通用擴展，包括先進的免疫學平台和數位健康工具的出現，疫苗研發者和經銷商的角色正在從單純的產品供應商轉變為提供端到端預防和監測解決方案的綜合合作夥伴。

突破性的科學突破、平台創新以及相關人員優先事項的轉變如何重新定義跨物種疫苗的開發、供應和部署。

過去十年，整個動物健康領域經歷了數次變革性變化，這些變化正在重塑疫苗的發現、生產、供應和部署方式。其中一項關鍵的科學轉變是平台技術的成熟，這些技術能夠加速抗原發現並實現模組化疫苗建構。這些平台縮短了研發週期，並能夠對新出現的病原體做出快速反應。同時，精準畜牧業和數位監測系統正在產生更高解析度的流行病學數據，以前所未有的速度建立回饋迴路，從而為疫苗設計和部署策略提供資訊。

分析 2025 年美國關稅政策對動物疫苗供應鏈、製造地選擇、價格趨勢和全球貿易模式的累積影響。

美國2025年關稅政策的調整進一步加劇了貿易的複雜性，對全球供應鏈和動物保健產業的籌資策略產生了連鎖反應。這種累積影響推高了疫苗生產中使用的生物原料、特殊試劑和設備的進口成本，迫使製造商重新評估籌資策略和成本轉嫁方式。為此，許多公司加快了替代供應商的認證進程，考慮將製造地遷至更靠近需求中心的地方，並擴大產能以降低關稅風險。

透過對動物種類、疫苗技術、給藥途徑、疾病類別和最終用戶進行詳細的細分分析，揭示了有針對性的機會和風險。

市場區隔為將宏觀趨勢轉化為針對特定動物種類、平台、給藥途徑、疾病和最終用途的策略提供了切實可行的觀點。就動物種類而言，市場涵蓋水產養殖、牛、伴侶動物、馬、家禽和豬，其中伴侶動物又細分為貓狗。每個子類別都有其獨特的購買動機、給藥模式和監管途徑，因此都需要相應的商業化策略。就疫苗技術而言，目前可用的平台包括結合疫苗、去活化疫苗、減毒活病毒疫苗、重組疫苗、次單元疫苗和類毒素疫苗。每種技術在生產複雜性、低溫運輸要求和療效差異方面都存在權衡，因此需要不同的定價和實證策略。給藥途徑（注射、鼻腔、口服）影響疫苗的擴散曲線和給藥成本，而非侵入性給藥途徑則為大規模生產系統減輕勞動力負擔提供了機會。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和比較優勢揭示了需求模式、製造地和法規環境。

區域趨勢對製造地地點、監管合規計畫和打入市場策略等策略選擇有顯著影響。在美洲，需求主要集中在伴侶動物照護和商業牲畜的生物安全方面，這得益於成熟的經銷網路和獸醫服務業。法規環境特點是核准流程結構完善，但對臨床和安全資料的要求很高。在歐洲、中東和非洲地區，區域差異是一大挑戰。西歐對高階伴侶動物產品和先進的動物福利標準有著很高的需求，而其他次區域則呈現出不同的監管能力和疾病流行程度，因此需要靈活的註冊和證據策略。在亞太地區，水產養殖的快速成長以及家禽和生豬生產的集約化帶來了巨大的商機，但企業必須應對不同的管理體制、當地的生產獎勵，以及某些市場對本地生產解決方案日益成長的偏好。

動物疫苗產業的競爭格局以及主要企業和創新者在夥伴關係、併購活動、產能投資和平台差異化方面採取的策略性舉措。

動物疫苗市場的競爭格局由兩大構面構成：規模與創新。成熟的動物用藥品公司在分銷網路、監管專業知識和大規模生產能力方面保持優勢，使其能夠服務於包括大規模農業企業和全球連鎖獸醫院在內的廣泛終端用戶。然而，隨著小規模生物技術公司和平台創新者開發出能夠提高疫苗效力、安全性和易用性的重組構建體、載體疫苗和新型佐劑系統，它們的影響力正在不斷增強。合約研發生產機構（CDMO）在幫助成熟企業和新參與企業擴大生產規模方面發揮著至關重要的作用，使它們無需投入大量資金來擁有完整的生產設施。

為產業領導者提供切實可行的策略建議，以利用技術、供應鏈韌性、監管合作和以客戶為中心的商業化方法。

領導者應在技術、供應鏈、監管和商業化等方面採取果斷行動，將市場複雜性轉化為競爭優勢。優先投資於能夠實現抗原柔軟性和可擴展生產的平台技術，縮短概念驗證研發週期，並專注於能夠快速應對不斷變化的病原體情況的重組和模組化方法。同時，應實現關鍵原料供應商網路的多元化，並制定緊急時應對計畫，包括經認證的替代來源和靈活的生產結構，以應對地緣政治因素和關稅相關的干擾。

嚴謹的調查方法說明：一手訪談、二手資訊、監管與專利分析、臨床證據評估、以及多方面的資料匹配方法。

本分析所依據的研究整合了定性和定量信息，以確保其可靠性和可操作性。主要研究包括對疫苗研發公司的高階主管、生產負責人和監管專家，以及大型終端使用者（例如綜合農業企業和多站點獸醫診所）進行結構化訪談。次要分析則利用了同行評審文獻、監管指導文件、臨床試驗註冊信息、專利申請和公開的公司信息，以驗證相關趨勢並檢驗有關技術成熟度和商業性趨勢的說法。供應鏈圖譜和情境分析用於評估貿易政策變化的影響，並評估關稅相關變化對採購的影響。

概述獸用疫苗領域在應對技術變革、貿易逆風和不斷變化的終端用戶期望方面所面臨的風險、策略機會和優先事項。

總之，獸用疫苗產業正處於策略轉折點，科學創新、政策趨勢和不斷變化的終端用戶期望在此交匯，亟需重塑競爭優勢。抗原設計和平台柔軟性的技術進步為伴侶動物、家畜和水產養殖的疾病管理開闢了新途徑，而貿易和關稅壓力則凸顯了供應鏈韌性和適應性籌資策略的必要性。基於動物種類、疫苗技術、給藥途徑、目標疾病和終端用戶背景的細分，為優先投資和定製商業化計劃提供了一個切實可行的框架。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 獸用與動物疫苗市場：依產品類型分類

  • 活病毒疫苗
  • 去活化疫苗
  • 次單元疫苗和重組疫苗
  • 病毒載體疫苗

第9章 獸用及動物疫苗市場：依給藥途徑分類

  • 腸外
  • 口服
  • 外用

第10章 獸用及動物疫苗市場：依目標疾病分類

  • 病毒性疾病
    • 狂犬病
    • 口蹄疫
    • 新城疫
    • 犬小病毒
    • 犬瘟熱
    • 貓泛白血球減少症
    • 傳染性牛鼻氣管炎
  • 細菌性疾病
    • 布氏桿菌症
    • 鉤端螺旋體病
    • 梭狀菌感染
    • 巴氏桿菌症
    • 大腸桿菌感染
  • 寄生蟲病
  • 黴菌感染疾病

第11章 獸用及動物疫苗市場：依技術平台分類

  • 傳統疫苗
  • 先進疫苗
  • 新的配送系統

第12章 獸用與動物疫苗市場：依價態分類

  • 單價疫苗
  • 多價疫苗

第13章 獸用與動物疫苗市場：依動物類型分類

  • 伴侶動物
    • 狗
    • 貓
    • 馬
  • 肉類動物
    • 牛
    • 豬
    • 家禽
    • 綿羊/山羊
    • 水產養殖
  • 野生動物和動物園動物

第14章 獸用及動物疫苗市場：依通路分類

  • 動物醫院
  • 零售藥房
  • 網路藥房

第15章 獸用與動物疫苗市場：依最終用戶分類

  • 獸醫醫院和診所
  • 畜牧場及生產設施
  • 測試機構
  • 研究機構和大學
  • 政府和公共衛生機構

第16章 獸用及動物疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 獸用及動物疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 獸藥與動物疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國：獸藥和動物疫苗市場

第20章：中國：獸藥和動物疫苗市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Arko Corp.
  • Bimeda Biologicals Inc
  • Biogenesis Bago SA
  • Biogenesis Bago SA
  • Bioveta, as
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health
  • Hester Biosciences Limited
  • Hipra SA
  • Huvepharma, Inc.
  • Indian Immunologicals Limited
  • Indian Immunologicals Ltd.
  • Jinyu Bio-technology Co., Ltd.
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • MEVAC
  • Neogen Corporation
  • Nisseiken Co., Ltd.
  • Pfizer, Inc.
  • Phibro Animal Health Corporation
  • Qingdao Yebio Biological Engineering Co., Ltd.
  • SAN Group
  • Seppic by Air Liquide Healthcare
  • SK Bioscience
  • Vaxxinova
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-034B500303A8

The Veterinary/Animal Vaccines Market was valued at USD 15.05 billion in 2025 and is projected to grow to USD 16.05 billion in 2026, with a CAGR of 6.89%, reaching USD 24.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.05 billion
Estimated Year [2026] USD 16.05 billion
Forecast Year [2032] USD 24.01 billion
CAGR (%) 6.89%

Comprehensive overview of the veterinary vaccines landscape revealing key drivers, stakeholder roles, technological progress, and regulatory interactions shaping strategies

The veterinary vaccines domain is in the midst of a structural transformation that is altering scientific paradigms, commercial strategies, and the operational footprints of manufacturers and service providers. Stakeholders across research institutions, clinical practice, farming operations, and regulatory bodies are converging around shared objectives: improved disease control, enhanced animal welfare, and resilient supply chains. As the scientific base expands to include advanced immunology platforms and digital health tools, the roles of vaccine developers and distributors are evolving from pure product suppliers to integrated partners offering end-to-end prevention and surveillance solutions.

Moreover, regulatory systems are increasingly harmonized in principle but remain heterogeneous in practice, prompting firms to design regulatory strategies that balance regional compliance with global scalability. Concurrently, consumer and producer expectations for safety, traceability, and sustainability are raising the bar for product evidence and lifecycle transparency. Taken together, these dynamics demand strategic clarity: organizations must prioritize platform investments, cultivate cross-sector partnerships, and align commercial models with shifting end-user behaviors. This introduction sets the stage for an evidence-driven exploration of how technological advances, trade dynamics, and market segmentation intersect to create both immediate challenges and durable opportunities in the veterinary vaccines landscape.

How transformative scientific breakthroughs, platform innovations, and shifting stakeholder priorities are redefining vaccine development, delivery, and adoption across species

The last decade has seen several transformative shifts that are recalibrating how vaccines are discovered, produced, delivered, and adopted across animal health sectors. A significant scientific shift is the maturation of platform technologies that accelerate antigen discovery and enable modular vaccine constructs; these platforms shorten development cycles and facilitate rapid responses to emergent pathogens. In parallel, precision livestock farming and digital surveillance systems are generating higher-resolution epidemiological data, creating feedback loops that inform vaccine design and deployment strategies more rapidly than before.

Commercially, there is a pronounced pivot toward value-based propositions that emphasize disease prevention economics, herd health optimization, and integrated service offerings-moving beyond transactional sales of products to subscription-style or outcome-oriented contracts. Supply chains are being redesigned for resilience: strategic nearshoring, capacity redundancy, and diversified supplier networks are becoming standard risk mitigants. Regulatory evolution is also notable, with some jurisdictions experimenting with streamlined pathways for novel platforms while maintaining rigorous safety and efficacy standards. These converging shifts mean that organizations able to integrate scientific agility, data-driven decision-making, and robust commercial models will gain disproportionate advantage. Consequently, leaders must align R&D priorities, manufacturing investments, and stakeholder engagement to capture the upside of these structural transitions.

Analyzing the cumulative effects of United States tariff policies in 2025 on supply chains, manufacturing choices, pricing dynamics, and global trade patterns for animal vaccines

United States tariff policy adjustments in 2025 introduced a layer of trade complexity that reverberated across global supply chains and procurement strategies in the animal health sector. The cumulative effect increased imported input costs for raw biological materials, specialized reagents, and equipment used in vaccine manufacturing, prompting manufacturers to reassess sourcing strategies and cost pass-through approaches. In response, many firms expedited qualification of alternative suppliers and evaluated relocation or expansion of manufacturing capacity closer to demand centers to mitigate tariff exposure.

These shifts also influenced commercial pricing negotiations and contract structures with distributors and large purchasers such as integrated producers and veterinary chains. Procurement teams sought greater transparency around landed costs and inventory planning, which in turn pushed manufacturers to strengthen supply chain analytics and scenario planning capabilities. Trade diversion patterns emerged as companies shifted procurement to tariff-favored partners, yet such reconfiguration created secondary risks including longer qualification timelines, variable supplier quality, and the need for additional regulatory filings.

From a strategic perspective, the tariff environment accelerated two durable trends: the economics of localized manufacturing for strategic SKUs and the emphasis on building supplier redundancy for critical inputs. Firms that had previously invested in flexible manufacturing platforms found it easier to adapt production mixes and maintain supply continuity. Looking ahead, organizations must continue to refine sourcing strategies, engage proactively with trade and regulatory stakeholders, and structure commercial agreements that recognize the potential for future policy shocks while preserving customer access to essential vaccines.

Deep segmentation insights across animal types, vaccine technologies, administration routes, disease categories, and end users to uncover targeted opportunities and risks

Segmentation offers a practical lens to translate macro trends into targeted strategies by species, platform, administration route, disease, and end-use context. When considering animal type, the market spans aquaculture, cattle, companion animals, equine, poultry, and swine with companion animals further dissected into cats and dogs-each subcategory exhibits distinct purchase drivers, dosing paradigms, and regulatory pathways that demand tailored commercialization approaches. On vaccine technology, choices range from conjugate, killed/inactivated, live attenuated, recombinant, subunit, to toxoid platforms; each technology carries trade-offs in manufacturing complexity, cold-chain demands, and differentiating claims, and therefore requires distinct pricing and evidentiary strategies. Route of administration-injectable, nasal, and oral-shapes adoption curves and administration cost profiles, with noninvasive routes presenting opportunities to lower labor burdens in mass production systems.

Disease type segmentation across bacterial, parasitic, and viral targets informs R&D prioritization and surveillance investments since pathogen biology and epidemiology dictate the feasibility of sterilizing immunity versus disease mitigation. Finally, end-user segmentation across clinics, farms, and veterinary hospitals-with farms further delineated into aquaculture farms, cattle farms, equine facilities, poultry farms, and swine farms-clarifies distribution channels and after-sales service needs; for example, aquaculture and poultry operations emphasize bulk dosing logistics and administration technologies, while clinics and veterinary hospitals prioritize companion animal brands, safety profiles, and client communication tools. Integrating these segmentation perspectives enables firms to design portfolio strategies that match product attributes with user willingness to pay, operational constraints, and regulatory requirements, thereby improving product uptake and lifecycle management.

Regional dynamics and comparative advantages across the Americas, Europe Middle East and Africa, and Asia-Pacific revealing demand patterns, manufacturing hubs, and regulatory climates

Regional dynamics materially shape strategic choices in manufacturing footprint, regulatory planning, and go-to-market approaches. In the Americas, demand is disproportionately weighted toward companion animal care and commercial livestock biosecurity, supported by established distribution networks and a mature veterinary services sector; the regulatory environment is characterized by well-developed pathways but significant expectations for clinical and safety data. In Europe, Middle East & Africa, heterogeneity is the primary challenge: Western Europe displays high demand for premium companion animal products and progressive animal welfare standards, while other subregions feature variable regulatory capacity and differing disease prevalence that call for adaptable registration and evidence strategies. In the Asia-Pacific region, rapid growth of aquaculture and intensification of poultry and swine production present large-scale opportunities, but companies must navigate diverse regulatory regimes, local manufacturing incentives, and a rising preference for locally produced solutions in some markets.

These regional contrasts suggest distinct investment priorities: Americas-focused strategies emphasize branding, data-driven value propositions for clinics and veterinary hospitals, and integrated customer engagement; Europe, Middle East & Africa requires flexible regulatory teams and tailored market-access plans; Asia-Pacific calls for scalable production options, partnerships with local players, and disease surveillance investments that reflect regional burden. Firms that harmonize global R&D platforms with region-specific commercialization playbooks will achieve faster adoption and higher operational efficiency across these three broad territories.

Competitive landscape and strategic moves by leading companies and innovators shaping partnerships, M&A activity, capacity investments, and platform differentiation in animal vaccines

Competitive dynamics in veterinary vaccines are characterized by a dual axis of scale and innovation. Established animal health companies retain advantages in distribution reach, regulatory expertise, and large-scale manufacturing capacity, enabling them to serve broad end-user bases such as major farming operations and global veterinary chains. However, smaller biotechnology firms and platform innovators are increasingly influential, pioneering recombinant constructs, vectored vaccines, and novel adjuvant systems that can improve efficacy, safety, and administration convenience. Contract development and manufacturing organizations (CDMOs) play an outsized role by enabling both incumbents and new entrants to scale production without the capital intensity of owning end-to-end facilities.

Strategic behaviors include targeted M&A to fill capability gaps, co-development partnerships to accelerate platform validation, and licensing arrangements that regionalize manufacturing while protecting core IP. Companies that emphasize platform flexibility and modular manufacturing gain the ability to pivot across antigens and species rapidly, creating competitive insulation against demand swings. Additionally, firms investing in field-level support-such as cold-chain solutions, training programs for on-farm administration, and digital monitoring tools-differentiate themselves by reducing adoption friction. In sum, the competitive battleground is shifting from single-product propositions to integrated solutions that combine scientific differentiation with operational excellence and customer-centric services.

Actionable strategic recommendations for industry leaders to capitalize on technology, supply chain resilience, regulatory engagement, and customer-centric commercialization approaches

Leaders should act decisively across technology, supply chain, regulatory, and commercial dimensions to convert market complexity into competitive advantage. Prioritize investment in platform technologies that enable antigen agility and scalable production, focusing on recombinant and modular approaches that reduce time to proof-of-concept and allow rapid response to shifting pathogen landscapes. Simultaneously, diversify supplier networks for critical inputs and develop contingency plans that include qualified alternate sources and flexible manufacturing arrangements to withstand geopolitical and tariff-related disruptions.

Strengthen regulatory engagement by allocating resources to harmonize dossiers across major territories and by participating in policy dialogues that shape accelerated pathways for novel platforms. Commercially, tailor go-to-market models to segmentation realities: cultivate relationships with clinics and veterinary hospitals for companion animal adoption, and design bulk dosing and administration solutions for farms, including aquaculture farms, poultry farms, cattle farms, equine facilities, and swine farms. Leverage digital tools for surveillance, post-market evidence generation, and customer support to build trust and demonstrate outcomes. Finally, pursue strategic collaborations with contract manufacturers, academic partners, and local market leaders to combine scale with innovation while preserving optionality and speed to market.

Rigorous research methodology describing primary interviews, secondary sources, regulatory and patent analysis, clinical evidence appraisal, and multi-source data triangulation approach

The research underpinning this analysis synthesized qualitative and quantitative inputs to ensure robustness and practical relevance. Primary research included structured interviews with senior executives across vaccine developers, manufacturing leaders, regulatory experts, and large end users such as integrated farming operations and multi-site veterinary practices. Secondary analysis drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, patent filings, and public corporate disclosures to triangulate trends and validate claims about technological readiness and commercial behavior. Supply chain mapping and scenario analysis were used to assess exposure to trade policy shifts and to evaluate the implications of tariff-driven sourcing pivots.

Data integrity was maintained through cross-validation across multiple independent sources and by testing alternative hypotheses during expert workshops. Where gaps existed, targeted follow-up interviews and vendor discussions were commissioned to ensure clarity on manufacturing timelines, platform capabilities, and regional regulatory nuances. The methodological approach balances depth and transparency, enabling stakeholders to understand both the evidence basis for conclusions and the practical implications for strategic planning, risk management, and investment prioritization.

Concluding synthesis of risks, strategic opportunities, and priority actions to navigate technological change, trade headwinds, and evolving end-user expectations in veterinary vaccines

In conclusion, the veterinary vaccines sector stands at a strategic inflection point where scientific innovation, policy dynamics, and evolving end-user expectations converge to reshape competitive advantage. Technological advances in antigen design and platform flexibility open new avenues for disease control across companion animals, livestock, and aquaculture, while trade and tariff pressures underscore the need for supply chain resilience and adaptive sourcing strategies. Segmentation across animal types, vaccine technologies, routes of administration, disease targets, and end-user contexts provides a pragmatic framework for prioritizing investments and customizing commercialization plans.

Executives who align R&D pipelines with operational agility, who invest in multi-regional regulatory competency, and who forge partnerships that combine scientific differentiation with manufacturing scale will be best positioned to capture long-term value. The pathways forward favor organizations that think systemically-integrating surveillance, vaccination programs, and post-market evidence generation-to deliver demonstrable outcomes for animal health, producer economics, and public health objectives. With disciplined execution and strategic foresight, stakeholders can convert current disruptions into durable competitive advantages.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary/Animal Vaccines Market, by Product Type

  • 8.1. Live Attenuated Vaccines
  • 8.2. Inactivated Vaccines
  • 8.3. Subunit & Recombinant Vaccines
  • 8.4. Viral Vector Vaccines

9. Veterinary/Animal Vaccines Market, by Route Of Administration

  • 9.1. Parenteral
  • 9.2. Oral
  • 9.3. Topical

10. Veterinary/Animal Vaccines Market, by Disease Indication

  • 10.1. Viral Diseases
    • 10.1.1. Rabies
    • 10.1.2. Foot-and-Mouth Disease
    • 10.1.3. Newcastle Disease
    • 10.1.4. Canine Parvovirus
    • 10.1.5. Canine Distemper
    • 10.1.6. Feline Panleukopenia
    • 10.1.7. Infectious Bovine Rhinotracheitis
  • 10.2. Bacterial Diseases
    • 10.2.1. Brucellosis
    • 10.2.2. Leptospirosis
    • 10.2.3. Clostridial Infections
    • 10.2.4. Pasteurellosis
    • 10.2.5. Colibacillosis
  • 10.3. Parasitic Diseases
  • 10.4. Fungal Infections

11. Veterinary/Animal Vaccines Market, by Technology Platform

  • 11.1. Conventional Vaccines
  • 11.2. Advanced Vaccines
  • 11.3. Novel Delivery Systems

12. Veterinary/Animal Vaccines Market, by Valency

  • 12.1. Monovalent Vaccines
  • 12.2. Multivalent Vaccines

13. Veterinary/Animal Vaccines Market, by Animal Type

  • 13.1. Companion Animals
    • 13.1.1. Dogs
    • 13.1.2. Cats
    • 13.1.3. Horses
  • 13.2. Food-Producing Animals
    • 13.2.1. Cattle
    • 13.2.2. Swine
    • 13.2.3. Poultry
    • 13.2.4. Sheep & Goats
    • 13.2.5. Aquaculture
  • 13.3. Wildlife & Zoo Animals

14. Veterinary/Animal Vaccines Market, by Distribution Channel

  • 14.1. Veterinary Clinics
  • 14.2. Retail Pharmacies
  • 14.3. Online Pharmacies

15. Veterinary/Animal Vaccines Market, by End User

  • 15.1. Veterinary Hospitals & Clinics
  • 15.2. Animal Farms & Production Units
  • 15.3. Reference Laboratories
  • 15.4. Research Institutes & Universities
  • 15.5. Government & Public Health Agencies

16. Veterinary/Animal Vaccines Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Veterinary/Animal Vaccines Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Veterinary/Animal Vaccines Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Veterinary/Animal Vaccines Market

20. China Veterinary/Animal Vaccines Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Arko Corp.
  • 21.6. Bimeda Biologicals Inc
  • 21.7. Biogenesis Bago S.A.
  • 21.8. Biogenesis Bago S.A.
  • 21.9. Bioveta, a.s.
  • 21.10. Boehringer Ingelheim International GmbH
  • 21.11. Ceva Sante Animale
  • 21.12. Dechra Pharmaceuticals PLC
  • 21.13. Elanco Animal Health Incorporated
  • 21.14. Endovac Animal Health
  • 21.15. Hester Biosciences Limited
  • 21.16. Hipra S.A.
  • 21.17. Huvepharma, Inc.
  • 21.18. Indian Immunologicals Limited
  • 21.19. Indian Immunologicals Ltd.
  • 21.20. Jinyu Bio-technology Co., Ltd.
  • 21.21. Kemin Industries, Inc.
  • 21.22. Merck & Co., Inc.
  • 21.23. MEVAC
  • 21.24. Neogen Corporation
  • 21.25. Nisseiken Co., Ltd.
  • 21.26. Pfizer, Inc.
  • 21.27. Phibro Animal Health Corporation
  • 21.28. Qingdao Yebio Biological Engineering Co., Ltd.
  • 21.29. SAN Group
  • 21.30. Seppic by Air Liquide Healthcare
  • 21.31. SK Bioscience
  • 21.32. Vaxxinova
  • 21.33. Virbac S.A.
  • 21.34. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE PARVOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE PARVOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE PARVOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE DISTEMPER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE DISTEMPER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE DISTEMPER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FELINE PANLEUKOPENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FELINE PANLEUKOPENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FELINE PANLEUKOPENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INFECTIOUS BOVINE RHINOTRACHEITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INFECTIOUS BOVINE RHINOTRACHEITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INFECTIOUS BOVINE RHINOTRACHEITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BRUCELLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BRUCELLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BRUCELLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PASTEURELLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PASTEURELLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PASTEURELLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COLIBACILLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COLIBACILLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COLIBACILLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONVENTIONAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONVENTIONAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONVENTIONAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ADVANCED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ADVANCED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ADVANCED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NOVEL DELIVERY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NOVEL DELIVERY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NOVEL DELIVERY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MONOVALENT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MONOVALENT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MONOVALENT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY WILDLIFE & ZOO ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY WILDLIFE & ZOO ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY WILDLIFE & ZOO ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL FARMS & PRODUCTION UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL FARMS & PRODUCTION UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL FARMS & PRODUCTION UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES & UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES & UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES & UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 279. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 280. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 281. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 285. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET